Ligand id: 7580

Name: ocrelizumab

Compound class Antibody
Approved drug? Yes (FDA (2017), EMA (2018))
International Nonproprietary Names
INN number INN
8636 ocrelizumab
2H7 | Ocrevus® | PRO70769 | RG1594
Ocrelizumab is a humanized IgG1 anti-CD20 monoclonal antibody, approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). This is the first therapeutic to gain approval for both of these forms of MS. Ocrelizumab is a modified version of rituximab, developed as a substitute in response to expiration of rituximab patent protection.
The submission documentation for the antibody's INN application contains the peptide sequences for the heavy and light chains of the antibody. BLAST searches of patented peptide sequences reveals identical matches with peptides claimed in patent WO2004056312, which resolve to clones 2H7.v16 and 2H7.v31 [1].
Database Links
Specialist databases
IMGT/mAb-DB 227
Other databases
GtoPdb PubChem SID 223365915
Search PubMed clinical trials ocrelizumab
Search PubMed titles ocrelizumab
Search PubMed titles/abstracts ocrelizumab
Wikipedia Ocrelizumab